{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T12:06:49Z","timestamp":1785240409333,"version":"3.55.0"},"reference-count":33,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T00:00:00Z","timestamp":1779753600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.clml.2026.05.003","type":"journal-article","created":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T06:59:20Z","timestamp":1779173960000},"page":"419-422","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["SOHO State of the Art Updates and Next Questions | Early Stage Hodgkin Lymphoma\u2014Are We Ready for Novel Agents?"],"prefix":"10.1016","volume":"26","author":[{"given":"Joseph G.","family":"Schroers-Martin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ranjana","family":"Advani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.clml.2026.05.003_bib0001","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1080\/10428190903040048","article-title":"Report on the first international workshop on interim-PET scan in lymphoma","volume":"50","author":"Meignan","year":"2009","journal-title":"Leuk Lymphoma"},{"issue":"1","key":"10.1016\/j.clml.2026.05.003_bib0002","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1200\/JCO.23.01177","article-title":"Long-term follow-up of the response-adjusted therapy for advanced Hodgkin lymphoma trial","volume":"42","author":"Luminari","year":"2024","journal-title":"J Clin Oncol"},{"issue":"10114","key":"10.1016\/j.clml.2026.05.003_bib0003","doi-asserted-by":"crossref","first-page":"2790","DOI":"10.1016\/S0140-6736(17)32134-7","article-title":"PET-guided treatment in patients with advanced-stage Hodgkin's lymphoma (HD18): final results of an open-label, international, randomised phase 3 trial by the German Hodgkin Study Group","volume":"390","author":"Borchmann","year":"2017","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.clml.2026.05.003_bib0004","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1200\/JCO.2017.75.2543","article-title":"Early chemotherapy intensification with escalated BEACOPP in patients with advanced-stage Hodgkin lymphoma with a positive interim positron emission tomography\/computed tomography scan after two ABVD cycles: long-term results of the GITIL\/FIL HD 0607 trial","volume":"36","author":"Gallamini","year":"2018","journal-title":"J Clin Oncol"},{"issue":"15","key":"10.1016\/j.clml.2026.05.003_bib0005","first-page":"1238","article-title":"Five-year follow-up of SWOG S0816: limitations and values of a PET-adapted approach with stage III\/IV Hodgkin lymphoma","volume":"134","author":"Stephens","year":"2019","journal-title":"Blood Am Soc Hematol"},{"issue":"2","key":"10.1016\/j.clml.2026.05.003_bib0006","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/S1470-2045(18)30784-8","article-title":"PET-adapted treatment for newly diagnosed advanced Hodgkin lymphoma (AHL2011): a randomised, multicentre, non-inferiority, phase 3 study","volume":"20","author":"Casasnovas","year":"2019","journal-title":"Lancet Oncol"},{"issue":"17","key":"10.1016\/j.clml.2026.05.003_bib0007","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1056\/NEJMoa1408648","article-title":"Results of a trial of PET-directed therapy for early-stage Hodgkin\u2019s lymphoma","volume":"372","author":"Radford","year":"2015","journal-title":"N Engl J Med"},{"issue":"31","key":"10.1016\/j.clml.2026.05.003_bib0008","doi-asserted-by":"crossref","first-page":"2835","DOI":"10.1200\/JCO.19.00964","article-title":"Positron emission tomography\u2013guided treatment in early-stage favorable Hodgkin lymphoma: final results of the international, randomized phase III HD16 trial by the German Hodgkin study group","volume":"37","author":"Fuchs","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2026.05.003_bib0009","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2016.68.6394","article-title":"Early positron emission tomography response-adapted treatment in stage I and II hodgkin lymphoma: final results of the randomized EORTC\/LYSA\/FIL H10 trial","volume":"35","author":"Andr\u00e9","year":"2017","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.clml.2026.05.003_bib0010","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1200\/JCO.23.01745","article-title":"Long-term follow-up of the response-adapted intergroup EORTC\/LYSA\/FIL H10 trial for localized Hodgkin lymphoma","volume":"42","author":"Federico","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2026.05.003_bib0011","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1182\/blood-2024-200662","article-title":"Involved field radiotherapy versus no further treatment in patients with newly diagnosed stage 1A or 2A Hodgkin lymphoma and a \u2018negative\u2019 PET scan after 3 cycles ABVD. Survival and cause of death after a median of 16 years follow-up in the UK RAPID trial","volume":"144","author":"Radford","year":"2024","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.clml.2026.05.003_bib0012","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1056\/NEJMoa2206125","article-title":"Overall survival with brentuximab vedotin in stage III or IV Hodgkin\u2019s lymphoma","volume":"387","author":"Ansell","year":"2022","journal-title":"N Engl J Med"},{"issue":"15","key":"10.1016\/j.clml.2026.05.003_bib0013","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1056\/NEJMoa2405888","article-title":"Nivolumab+ AVD in advanced-stage classic Hodgkin\u2019s lymphoma","volume":"391","author":"Herrera","year":"2024","journal-title":"N Engl J Med"},{"issue":"10450","key":"10.1016\/j.clml.2026.05.003_bib0014","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/S0140-6736(24)01315-1","article-title":"Assessing the efficacy and tolerability of PET-guided BrECADD versus eBEACOPP in advanced-stage, classical Hodgkin lymphoma (HD21): a randomised, multicentre, parallel, open-label, phase 3 trial","volume":"404","author":"Borchmann","year":"2024","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.clml.2026.05.003_bib0015","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1200\/JCO.21.01281","article-title":"Brentuximab vedotin plus AVD for first-line treatment of early-stage unfavorable Hodgkin lymphoma (BREACH): a multicenter, open-label, randomized, phase II trial","volume":"41","author":"Fornecker","year":"2023","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.clml.2026.05.003_bib0016","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1001\/jamaoncol.2020.0750","article-title":"Efficacy of nivolumab and AVD in early-stage unfavorable classic Hodgkin lymphoma: the randomized phase 2 German Hodgkin Study Group NIVAHL trial","volume":"6","author":"Br\u00f6ckelmann","year":"2020","journal-title":"JAMA Oncol"},{"issue":"6","key":"10.1016\/j.clml.2026.05.003_bib0017","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1200\/JCO.22.02355","article-title":"Nivolumab and doxorubicin, vinblastine, and dacarbazine in early-stage unfavorable Hodgkin lymphoma: final analysis of the randomized German Hodgkin Study Group Phase II NIVAHL trial","volume":"41","author":"Br\u00f6ckelmann","year":"2023","journal-title":"J Clin Oncol"},{"issue":"20","key":"10.1016\/j.clml.2026.05.003_bib0018","doi-asserted-by":"crossref","first-page":"2257","DOI":"10.1200\/JCO.21.00108","article-title":"Brentuximab vedotin combined with chemotherapy in patients with newly diagnosed early-stage, unfavorable-risk Hodgkin lymphoma","volume":"39","author":"Kumar","year":"2021","journal-title":"J Clin Oncol"},{"issue":"Supplement 1","key":"10.1016\/j.clml.2026.05.003_bib0019","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1182\/blood-2022-156382","article-title":"Brentuximab vedotin combined with chemotherapy in newly diagnosed, early-stage, unfavorable-risk Hodgkin lymphoma: extended follow-up with evaluation of baseline metabolic tumor volume and PET2","volume":"140","author":"Stuver","year":"2022","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.clml.2026.05.003_bib0020","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1182\/bloodadvances.2022008420","article-title":"Brentuximab vedotin plus doxorubicin and dacarbazine in nonbulky limited-stage classical Hodgkin lymphoma","volume":"7","author":"Abramson","year":"2023","journal-title":"Blood Adv"},{"issue":"3","key":"10.1016\/j.clml.2026.05.003_bib0021","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1182\/blood.2024024681","article-title":"Brentuximab vedotin, nivolumab, doxorubicin, and dacarbazine for advanced-stage classical Hodgkin lymphoma","volume":"145","author":"Lee","year":"2025","journal-title":"Blood"},{"issue":"15","key":"10.1016\/j.clml.2026.05.003_bib0022","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1182\/blood.2025030190","article-title":"Brentuximab vedotin and nivolumab in combination with chemotherapy for non-bulky, early-stage classical Hodgkin lymphoma","volume":"147","author":"Abramson","year":"2026","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.clml.2026.05.003_bib0023","doi-asserted-by":"crossref","first-page":"2548","DOI":"10.1182\/bloodadvances.2020001871","article-title":"ABVD followed by BV consolidation in risk-stratified patients with limited-stage Hodgkin lymphoma","volume":"4","author":"Park","year":"2020","journal-title":"Blood Adv"},{"key":"10.1016\/j.clml.2026.05.003_bib0024","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1182\/blood-2024-202207","article-title":"PET-directed therapy with ABVD vs. Bv+ AVD followed by nivolumab in patients with early stage Hodgkin lymphoma: a propensity score matched analysis of CALGB50604 and ACCRULY1601","volume":"144","author":"Park","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.clml.2026.05.003_bib0025","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1182\/blood-2024-204113","article-title":"A randomized phase 2 study incorporating nivolumab and brentuximab vedotin into radiation-free treatment of early stage classic Hodgkin Lymphoma","volume":"144","author":"LaCasce","year":"2024","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.clml.2026.05.003_bib0026","doi-asserted-by":"crossref","first-page":"e274","DOI":"10.1016\/S2352-3026(26)00068-2","article-title":"Very early FDG-PET-guided targeted therapy in advanced Hodgkin lymphoma: primary results from the EORTC-1537-COBRA phase II trial","volume":"13","author":"Hutchings","year":"2026","journal-title":"Lancet Haematol"},{"issue":"10","key":"10.1016\/j.clml.2026.05.003_bib0027","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1182\/blood.2020007400","article-title":"Pembrolizumab followed by AVD in untreated early unfavorable and advanced-stage classical Hodgkin lymphoma","volume":"137","author":"Allen","year":"2021","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.clml.2026.05.003_bib0028","doi-asserted-by":"crossref","first-page":"2670","DOI":"10.1182\/bloodadvances.2022008116","article-title":"Sequential pembrolizumab and AVD are highly effective at any PD-L1 expression level in untreated Hodgkin lymphoma","volume":"7","author":"Allen","year":"2023","journal-title":"Blood Adv"},{"issue":"21","key":"10.1016\/j.clml.2026.05.003_bib0029","first-page":"2576","article-title":"Concurrent pembrolizumab with AVD for untreated classical Hodgkin lymphoma","volume":"141","author":"Lynch","year":"2023","journal-title":"Blood J"},{"key":"10.1016\/j.clml.2026.05.003_bib0030","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2025-8243","article-title":"Radiation-free therapy for the initial treatment of good prognosis early non-bulky HL, defined by a low metabolic tumor volume and a negative interim PET after 2 chemotherapy cycles. A phase II prospective rafting trial","volume":"146","author":"Filonenko","year":"2025","journal-title":"Blood"},{"key":"10.1016\/j.clml.2026.05.003_bib0031","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1097\/01.HS9.0000890820.12468.10","article-title":"P063: trial in progress: individualized immunotherapy in early-stage unfavorable Hodgkin lymphoma-the investigator-initiated phase II GHSG INDIE trial","volume":"6","author":"Br\u00f6ckelmann","year":"2022","journal-title":"HemaSphere"},{"issue":"16","key":"10.1016\/j.clml.2026.05.003_bib0032","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1200\/JCO.23.01386","article-title":"Doxorubicin exposure and breast cancer risk in survivors of adolescent and adult Hodgkin lymphoma","volume":"42","author":"Neppelenbroek","year":"2024","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.clml.2026.05.003_bib0033","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1038\/s41571-022-00600-w","article-title":"Immune-checkpoint inhibitors: long-term implications of toxicity","volume":"19","author":"Johnson","year":"2022","journal-title":"Nat Rev Clin Oncol"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265026001461?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265026001461?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T11:58:05Z","timestamp":1785239885000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265026001461"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":33,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["S2152265026001461"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2026.05.003","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"SOHO State of the Art Updates and Next Questions | Early Stage Hodgkin Lymphoma\u2014Are We Ready for Novel Agents?","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2026.05.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}